Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

Outline of Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02600468

Enrollment

671

Registered

2015-11-09

Start date

2013-09-30

Completion date

2015-12-31

Last updated

2017-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The purpose of this study to collect information on the safety, especially serious infections and malignancies, and efficacy of the long-term use of ORENCIA Intravenous Infusion 250mg in patients with rheumatoid arthritis.

Interventions

DRUGOrencia

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are beginning to receive the treatment with ORENCIA Intravenous Infusion 250mg under the approved indications, dosage, and administration * Have available HAQ data * Have available DAS28-ESR or DAS28- CRP data * Have no past or present history of malignancies * Are expected to be followed up for 3 years

Design outcomes

Primary

Measure	Time frame
Safety measured by number of Adverse events and laboratory abnormalities associated with adverse events	3 years

Secondary

Measure	Time frame
Efficacy measured by Patient's survival	3 years
Efficacy measured by development of malignancies after treatment discontinuation	3 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026